title: [An alternative to conventional antibiotic therapy in respiratory infections--Bioparox Spray].
abstract: As the main target of influenza viral aggression, the respiratory tract is subject to easier bacterial infection superimposition. The researchers from Les Laboratoires Servier--France, managed to isolate a substance--fusafungine--from the microspore of the fungus Fusarium lateritium, which demonstrates unique anti-inflammatory and antibiotic action, and is the active ingredient of Bioparox Spray, an inhalant. The principal indications of Bioparox Spray for treatment of respiratory tract infections fall within the range from the sinuses to the finest alveolar duct, namely: rhinitis, sinusitis, tonsillitis, pharyngitis, laryngitis, tracheitis and bronchitis. In terms of technology Bioparox is unique due to the fact that 90% of the aerosol particles are less than one micron large, while generally the particles needed for penetration through the alveolar duct should be less than three microns. Due to such micronization, after inhalation Bioparox Spray reaches from the sinuses to the finest bronchial branches. Bioparox Spray possesses sound and broad antibiotic spectrum of action on the most common causative agents of respiratory infections, and more over, it acts upon Candida albicans, unlike the remaining broad-spectrum antibiotics. Bioparox Spray also has an independent anti-inflammatory effect by blocking the inflammation mediators: Bioparox Spray inhibits the synthesis of free radicals and the action of IL1 and TNF as pro-inflammatory factors, and it potentiates the action of IL2 and interferon-gamma which are anti-inflammatory factors. By its dual antibiotic and anti-inflammatory action Bioparox Spray is an excellent alternative to the conventional antibiotic therapy.
authors.forename: I
authors.initials: I
authors.lastname: Chalŭkov
mesh_terms: D000336:Aerosols / Q000008:administration & dosage; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D047630:Depsipeptides; D004311:Double-Blind Method; D005670:Fusarium; D006801:Humans; D012141:Respiratory Tract Infections / Q000188:drug therapy*
chemical_list: D000336:Aerosols; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D047630:Depsipeptides; C014001:fusafungin